MacroGenics | MGNX - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
AbbVie USD 5.57B 2.9B 2026-03
Amgen USD 1.51B 2.41B 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Biogen USD 377.7M 433.7M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Genmab DKK 55M 427M 2025-12
Geron USD -3.64M 27.5M 2026-03
Gilead Sciences USD 2.08B 1.56B 2025-12
J&J USD 7.82B 2.86B 2026-03
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
MacroGenics USD -36.77M 21.84M 2026-03
Merck USD 3.42B 3.32B 2025-12
Pfizer USD 5.18B 6.82B 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Xencor USD -128.64M 124.37M 2026-03